W-Type Meningitis Vaccine

AIM Persistence Biopharmaceutical Co., Ltd. is a professional and reliable manufacturer of W-Type Meningitis Vaccine. The protective efficacy of our Xin'er Cong® series vaccine against W-type meningococcal meningitis has been verified through international clinical trials. It not only precisely targets the W-type meningococcal meningitis that you are particularly concerned about but also addresses the potential risk of infection from other serotypes, perfectly adapting to the current complex epidemiological situation of meningococcal meningitis.

Why Is Preventing Meningitis so Important?

Meningococcal meningitis is an acute and highly contagious infectious disease caused by Neisseria meningitidis. Among the different serotypes, serotype W (W135) meningococcus is a major target for global meningitis control due to its strong transmissibility and high severity rate.

With increasingly frequent international travel, the risk of imported W-type meningococcal meningitis continues to rise. It can rapidly lead to serious complications such as sepsis and septic shock, posing a significant threat to the health of people of all ages, especially in cross-border travel and group living situations. Therefore, a W-type meningococcal vaccine is urgently needed for prevention.

Who Needs to Be Vaccinated Against Meningitis?

At present, it is only recommended for use in high-risk populations of children over 2 years old and adults in the following scope:

1. Those who travel to or live in high-risk areas, such as the African meningitis belt (epidemic areas of Group A, C, Y, and W135 Neisseria meningitidis).

2. Those who may come into contact with Group A, C, Y, and W135 Neisseria meningitidis from the air in laboratory or vaccine production work.

3. High-risk populations in areas where the national health administrative departments predict an outbreak of Group Y and W135 Neisseria meningitidis infection based on epidemiological investigations.

The quadrivalent meningococcal vaccine, in addition to covering type W, has added protection against the other three serotypes. It can effectively deal with the complex epidemic situation of meningococcal disease and provide you with more comprehensive protection. It is a more cost-effective choice.

The fatality rate of Group W is high and cannot be ignored

According to the data from NNDRS and the meningococcal disease single disease/specific disease surveillance information reporting management System, a total of 325 cases of meningococcal disease were reported across the country from 2015 to 2017, with 42 deaths. The fatality rate of the W group was the highest at 50.00%.

The mortality rates of meningococcal meningitis A, B, C, W, Y, others and ungrouped cases were reported in China from 2015 to 2017

[1] Li Junhong, Li Yixing, Wu Dan, et al. Analysis of the Epidemiological Characteristics of Meningococcal Meningitis in China from 2015 to 2017 [C]. //Proceedings of the 9th Forum on Basic Research and Application Technologies for Infectious Disease Prevention and Control. 2018:156-164.